From ESMO World Congress on Gastrointestinal Cancer 2023:
Patients undergoing resection of HER2-positive gastric or oesophagogastric junction cancer may benefit from use of trastuzumab alongside perioperative chemotherapy
Welcome to OncologyPRO – educational and scientific content for ESMO Members. Participants of some ESMO Meetings will have access to the Meeting resources section—limited to the meeting you attended. To gain full access to all the resources on this website, you must be an ESMO Member.
Please sign in using the username and password you created. To ensure a seamless browsing experience, we suggest that you sign in at the start of your visit.